Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
M&A Deal

Charles River Laboratories Shares Rise 5% After $470M Deal for Frontage Bioanalysis Assets

Charles River Laboratories to Acquire Frontage’s Bioanalysis Assets for $470M

+5.01% $337.52 when we broke this story → $354.42 at 11:49 AM ET, 9 Nov 2026

Charles River Laboratories has signed definitive agreements to acquire the bioanalysis and DMPK operations of Frontage Holdings Corporation for $470 million in cash. The transaction significantly expands the company's clinical testing footprint and reinforces its strategy to provide integrated solutions across the entire drug development lifecycle.

Woman, engineer, tech, electronics. Stock photo illustrating Charles River Laboratories International's M&A deal story.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · Healthcare · Photo: This_is_Engineering / Pixabay
Key numbers
Deal value$470M
Share of market cap2.9%
Share of annual revenue11.7%

Key highlights

  • Initial cash consideration of $470 million, subject to customary closing adjustments
  • Additional contingent payments of up to $75 million based on future business performance
  • Acquisition includes 150,000 square feet of laboratory space across two sites in Exton, Pennsylvania
  • Integration of approximately 340 scientific employees and a CLIA-certified central laboratory
  • Targeting a bioanalysis market sector projected to grow to $9 billion by 2031

What Is the Deal?

Charles River Laboratories (NYSE: CRL) is expanding its clinical-phase laboratory footprint through the $470 million acquisition of Frontage Holdings’ bioanalysis and DMPK operations. The deal, structured as an all-cash transaction, includes an additional earn-out provision of up to $75 million contingent on future performance. This strategic acquisition targets the Exton, Pennsylvania-based assets, which provide testing services for both small and large molecules. The company expects the transaction to conclude in the first half of 2027, pending required shareholder approvals and regulatory clearance.

Strategic Rationale

  • Expansion into the clinical bioanalysis market, projected to grow at 6% to 8% annually through 2031
  • Creation of integrated solutions that bridge the gap between preclinical and clinical testing phases
  • Enhancement of scientific leadership in biologics and complex drug modalities
  • Execution of the Pathway to Purpose strategy for long-term growth and value creation
  • Addition of specialized capacity including a CLIA-certified central laboratory

Financial Context

The $470 million initial consideration represents approximately 2.9% of Charles River’s $16.17 billion market capitalization. This acquisition follows a period of portfolio optimization, including the early 2026 divestitures of certain European discovery assets and CDMO businesses for approximately $145 million. As of late 2026, the company’s Discovery and Safety Assessment backlog remained robust at $2.03 billion. Management has indicated that the planned acquisition will leverage existing preclinical strengths to capitalize on the increasing demand for specialized assays in advanced therapies.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share price · last month
Line chart of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s share price over the last month, from $300.02 on 19 Oct → $335.52 on 16 Nov; our story on 9 Nov at $337.52.

Down 0.6% since our story on 9 Nov: $337.52 when we broke it → $335.52 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$300.02
20 Oct$315.45
21 Oct$344.87
22 Oct$339.66
23 Oct$345.37
26 Oct$357.27
27 Oct$358.84
28 Oct$373.98
29 Oct$376.10
30 Oct$359.41
2 Nov$338.54
3 Nov$351.87
4 Nov$326.29
5 Nov$313.02
6 Nov$337.52
9 Nov$353.34
10 Nov$345.80
11 Nov$342.69
12 Nov$340.81
13 Nov$337.97
16 Nov$335.52

Leadership Perspective

“The planned acquisition accelerates our strategy to expand our bioanalysis capabilities and enhance our offering in an attractive, high-growth market. As biologics and increasingly complex modalities become a larger part of development pipelines, clients are seeking scientific partners that can support programs from early development through the clinic.”

Birgit Girshick, Chief Executive Officer, Charles River Laboratories
Earlier announcements by CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
DateAnnouncementAmount
25 Feb 2026Divestiture of certain European Discovery Services assets to IQVIA Holdings Inc.Source: SEC filing$145.0 Million
25 Feb 2026Divestiture of CDMO and Cell Solutions businesses to GI PartnersSource: SEC filing–
12 Jan 2026Acquisition of K.F. (Cambodia) Ltd.Source: vectorshift.ai$510.0 Million
12 Jan 2026Acquisition of remaining ~79% stake in PathoQuest SASSource: vectorshift.ai$60.0 Million

Management commentary

“By adding Frontage’s clinical bioanalysis expertise, talented scientific team, and strong client relationships, we will be better positioned to meet those evolving needs.”

Birgit Girshick, Chief Executive Officer
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · financial snapshot
Share price$337.52
Market cap$16.2B
Revenue (annual)$4.0B
P/E (TTM)366.9×
1-month price change+12.39%
SectorHealthcareDiagnostics & Research

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Charles River Laboratories International, Inc. announcing the definitive agreement to acquire Frontage bioanalysis assets.

Read the filing ↗

Track CHARLES RIVER LABORATORIES INTERNATIONAL, INC. live

Get the next CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SEC filing seconds after it lands.

More in M&A & Deals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.